BioXcel Therapeutics, Inc. (BTAI) Earnings Call Analysis
NASDAQ · Healthcare · Biotechnology
Earnings Reports
-
BTAI Q3 2024: R&D Spending Down 74% as BXCL501 Pivotal Trials Advance
November 14, 2024
-
BioXcel Therapeutics (BTAI) Q2 2024: EGALMI Revenue Surges 141% as Home Agitation Trials Advance
August 06, 2024
-
BTAI Q1 2024: Egalmi Revenue Up 182% as Late-Stage Agitation Trials Set Dual Value Path
May 09, 2024
-
BTAI Q4 2023: Cash Runway Shrinks to Mid-2024 as Tranquility and Serenity Prioritized
March 12, 2024